A CJC-1295/Ipamorelin blend combines a growth hormone releasing hormone (GHRH) analogue with a growth hormone releasing peptide (GHRP). Together they work synergistically on different pathways to support growth hormone release.

Research protocols commonly use blends at doses equivalent to 100-300 mcg of each component, administered 1-2 times daily subcutaneously. Evening dosing before bed is often preferred to align with natural GH pulsatility.

Add bacteriostatic water slowly to the vial, directing the stream against the glass wall. Common reconstitution volumes are 2-3 mL. Gently swirl until dissolved. The calculator determines your per-injection volume based on the total vial content.